Omnicell, Inc.
OMCLHealthcareNASDAQHealth Information Services · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Omnicell, Inc. focuses on Health Information Services services and products. Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. At a $2.09B market cap, Omnicell, Inc. ranks as a mid-cap company within healthcare. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.
Market Cap
$2.09B
Beta
0.97
P/E (TTM)
106.67
P/E (Fwd)
20.90
EPS (TTM)
$0.43
EPS (Fwd)
$2.19
ROE
1.6%
ROA
1.2%
Cash
$239.2M
Total Debt
$202.2M
Free CF
$112.6M
52W Change
70.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $239.2M in cash comfortably exceeding the $202.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $112.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 1.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.13B (2021) to $1.18B (2025).
At over 50x earnings, OMCL carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Omnicell, Inc.'s trajectory.